Goldman Sachs Group Inc. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 314,591 shares of the company’s stock after selling 26,020 shares during the quarter. Goldman Sachs Group Inc. owned 0.37% of IDEXX Laboratories worth $207,146,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $28,000. Bell Investment Advisors Inc acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $34,000. Institutional & Family Asset Management LLC boosted its holdings in shares of IDEXX Laboratories by 216.7% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 57 shares of the company’s stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $39,000. Finally, Exane Derivatives bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $40,000. 84.92% of the stock is currently owned by hedge funds and other institutional investors.
IDXX has been the subject of several analyst reports. Atlantic Securities initiated coverage on IDEXX Laboratories in a research report on Tuesday, February 8th. They set an “overweight” rating and a $650.00 target price for the company. Bank of America lowered IDEXX Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Wednesday, February 2nd. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $663.67.
IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.02. The company had revenue of $836.55 million for the quarter, compared to analysts’ expectations of $836.47 million. IDEXX Laboratories had a net margin of 22.43% and a return on equity of 103.70%. IDEXX Laboratories’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 8.24 EPS for the current fiscal year.
In other news, Director Jonathan W. Ayers sold 250 shares of the business’s stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $509.70, for a total transaction of $127,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.06% of the company’s stock.
IDEXX Laboratories Profile (Get Rating)
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.